## Impact of FDA's Recent Draft Guidance on Participant Diversity

In this second of two parts on the developing participant diversity movement, sponsor, CRO, and site representatives discuss the impact of the FDA's recent draft guidance and the efforts they already are making to increase inclusivity in their trials.

### Key Discussions
- The necessity of attracting a diverse participant pool.
- Strategies being implemented to enhance inclusivity in clinical trials.

[Read more here](https://www.centerwatch.com/articles/26162-sponsors-already-heeding-fdas-call-for-diversity-planning-experts-say)

[Michael Causey's Clinical Trial Report with Chris Komelasky on SiteBridge's Community Engagement Approach](https://www.sitebridgeresearch.com/post/michael-causey-s-clinical-trial-report-with-chris-komelasky-on-sitebridge-s-community-engagement-app)

[Read about SiteBridge's partnership with Alliance Medical Ministry](https://www.sitebridgeresearch.com/post/sitebridge-partners-with-alliance-medical-ministry-amm-one-of-the-largest-free-and-charitable-cli)